Interesting post from Lyondell- In 2014, there
Post# of 30028
Posted On: 08/07/2014 11:24:07 AM
Interesting post from Lyondell-
In 2014, there are over 300 open clinical trials for Alzheimers....According to the U.S National Institutes of Health, there are over 300 clinical trials currently going on for Alzheimers. +40 of those are P3 Human trials and more are expected in the near future (a gerald term, which could mean several months to several years
.
To throw in a small example, ACAD's (a small biotech Comp) Pimavaserin recruited 199 patients in 2010 alone, multiply by $1k, and that's almost 200k alone just for a small biotech.
If, and that's a BIG "if" Lympro is even half of what GC claims it to be, even IF it's only 75% accurate. And IF we can commercialize this this year (with either will and act of a higher power). This is likely to generate significant/sustainable revenues.
On the same topic, a test that's more accurate will require less patients screened for a clinical trial, which means less sales for Lympro. So as long as Lympro is accepted as a standard, it doesn't matter what the accuracy is. As long as Comps use it, it will be great news for AMBS.
I apologize in advance for what some may perceive as a pump piece, but certainly a lot of great and exciting developements coming to light
In 2014, there are over 300 open clinical trials for Alzheimers....According to the U.S National Institutes of Health, there are over 300 clinical trials currently going on for Alzheimers. +40 of those are P3 Human trials and more are expected in the near future (a gerald term, which could mean several months to several years
. To throw in a small example, ACAD's (a small biotech Comp) Pimavaserin recruited 199 patients in 2010 alone, multiply by $1k, and that's almost 200k alone just for a small biotech.
If, and that's a BIG "if" Lympro is even half of what GC claims it to be, even IF it's only 75% accurate. And IF we can commercialize this this year (with either will and act of a higher power). This is likely to generate significant/sustainable revenues.
On the same topic, a test that's more accurate will require less patients screened for a clinical trial, which means less sales for Lympro. So as long as Lympro is accepted as a standard, it doesn't matter what the accuracy is. As long as Comps use it, it will be great news for AMBS.
I apologize in advance for what some may perceive as a pump piece, but certainly a lot of great and exciting developements coming to light
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼